Luminex, Exiqon to develop new microRNA products

By E. Janene Geiss

Philadelphia, Sept. 19 - Luminex Corp. and Exiqon AS announced Tuesday the signing of an agreement to co-develop and commercialize microRNA products.

Exiqon, a Copenhagen-based biotechnology company, said it will develop and manufacture microRNA products on behalf of the Luminex Bioscience Group based on Luminex's xMAP technology and Exiqon's Locked Nucleic Acid technology, according to a news release from Luminex, an Austin, Texas, biotechnology company.

MicroRNAs are a class of regulatory RNA molecules with widespread effects on gene regulation. Although recently identified as a new class of molecules, initial studies indicate that miRNAs may regulate as much as one-third of all genes in the genome.

MicroRNAs have already been found to have important roles in several types of cancers and in processes involved in cellular differentiation, officials said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.